Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion type Assertion NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_head.
- NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion wasGeneratedBy ECO_0000203 NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_provenance.
- NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion wasDerivedFrom befree-2016 NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_provenance.
- NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion SIO_000772 21247529 NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_provenance.
- NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion evidence source_evidence_literature NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_provenance.
- NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_assertion description "[The aim of this randomized, double-blind, placebo-controlled study was to measure reductions in circulating levels of high-sensitivity C-reactive protein, an established biomarker of inflammation associated with coronary artery disease, on MLN1202 treatment in patients at risk for atherosclerotic cardiovascular disease (≥2 risk factors for atherosclerotic cardiovascular disease and circulating high-sensitivity C-reactive protein >3 mg/L).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866328.RADoZZ-O858AZYnyY4r83145D1SPKDSY51z_5iHHqryeY130_provenance.